$ARWR earnings report

Arrowhead reported revenue of $75,253 (in thousands) for the three months ended June 30, 2026, compared with $27,767 (in thousands) for the three months ended June 30, 2025. The release identified commercial momentum for REDEMPLO, stating that prescription volume roughly doubled during the fiscal third quarter, more than 400 unique practitioners have prescribed the drug, and favorable policies are in place for the most significant U.S. payers. Marketing authorizations in the European Union and Australia added to the commercial footprint described in the release.

The expense base remained substantial. Research and development expense was 198,223 (in thousands), compared with 162,368 (in thousands), and selling, general and administrative expense was 47,123 (in thousands), compared with 30,949 (in thousands). Total operating expenses were 245,346 (in thousands), producing an operating loss of (170,093) (in thousands). Net loss attributable to Arrowhead Pharmaceuticals, Inc. was $ (194,280) (in thousands), or $ (1.36) per diluted share, versus $ (175,241) (in thousands), or $ (1.26) per diluted share.

Clinical execution was a central feature of the period. SHASTA-3 and SHASTA-4 met their primary and all prespecified secondary endpoints, with median triglyceride reductions of 79% and 81%, respectively. The company also reported a statistically significant 78% reduction in acute pancreatitis events versus placebo across the severe hypertriglyceridemia study population. Arrowhead completed enrollment in the YOSEMITE Phase 3 trial after increasing target enrollment from 60 participants to 70 patients following reported global patient and physician interest.

The June 30, 2026 balance sheet showed total cash resources of 1,566,886 (in thousands), consisting of $ 19,685 (in thousands) of cash, cash equivalents and restricted cash and 1,547,201 (in thousands) of available-for-sale securities. Total liabilities were $ 1,645,972 (in thousands), including 682,707 (in thousands) of convertible notes, net, 181,366 (in thousands) under the Credit Facility, and $ 392,512 (in thousands) related to the sale of future royalties. The Madrigal ARO-PNPLA3 license brought a $25 million upfront payment and provides eligibility for development, regulatory, and sales milestones of up to $975 million, plus tiered royalties.

The release did not provide revenue, expense, margin, or tax-rate financial guidance. Forward milestones include detailed SHASTA-3 and SHASTA-4 data on August 30, 2026, an anticipated plozasiran sNDA submission before the end of 2026 using the acquired priority review voucher, and anticipated YOSEMITE completion in mid-2027. The next reported catalysts therefore center on the detailed Phase 3 dataset, regulatory submission timing, REDEMPLO commercial adoption, and the scale of spending and losses alongside pipeline advancement.